{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelitis%2C+Transverse&page=2",
    "query": {
      "condition": "Myelitis, Transverse",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Myelitis%2C+Transverse&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T07:31:21.008Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06680037",
      "title": "A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "B-cell Mediated Autoimmune Disorders"
      ],
      "interventions": [
        {
          "name": "Azercabtagene zapreleucel (azer-cel)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "TG Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2025-05-06",
      "completion_date": "2030-01-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-20",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 8,
      "location_summary": "La Jolla, California • Ann Arbor, Michigan • Omaha, Nebraska + 5 more",
      "locations": [
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "Omaha",
          "state": "Nebraska"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Rochester",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06680037"
    },
    {
      "nct_id": "NCT05966467",
      "title": "Registry of Patients With AQP4+ NMOSD Treated With Alexion C5 Inhibitor Therapies",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder",
        "NMOSD",
        "AQP4+ NMOSD"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 122,
      "start_date": "2024-02-01",
      "completion_date": "2029-09-27",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 6,
      "location_summary": "Washington D.C., District of Columbia • Boston, Massachusetts • Chapel Hill, North Carolina + 3 more",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Plano",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05966467"
    },
    {
      "nct_id": "NCT04614454",
      "title": "High Frequency Impulse Therapy for Neuropathic Pain in NMOSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Neuromyelitis Optica"
      ],
      "interventions": [
        {
          "name": "High Frequency Impulse Therapy",
          "type": "DEVICE"
        },
        {
          "name": "High Frequency Impulse Therapy - Sham",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2021-06-07",
      "completion_date": "2025-01-15",
      "has_results": true,
      "last_update_posted_date": "2025-04-30",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04614454"
    },
    {
      "nct_id": "NCT01777412",
      "title": "Efficacy of Bevacizumab (Avastin) in Treatment of Acute NMO Exacerbations",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 10,
      "start_date": "2013-06",
      "completion_date": "2015-05",
      "has_results": true,
      "last_update_posted_date": "2015-08-21",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01777412"
    },
    {
      "nct_id": "NCT00179478",
      "title": "Long Term Study of Avonex Therapy Following a First Attack of Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Optic Neuritis",
        "Transverse Myelitis",
        "Acute Brainstem/Cerebellar Syndrome"
      ],
      "interventions": [
        {
          "name": "interferon beta 1a 30 ug IM once weekly",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 155,
      "start_date": "2001-02",
      "completion_date": "2009-03",
      "has_results": true,
      "last_update_posted_date": "2017-09-06",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 20,
      "location_summary": "Derby, Connecticut • Tampa, Florida • Atlanta, Georgia + 16 more",
      "locations": [
        {
          "city": "Derby",
          "state": "Connecticut"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Elk Grove",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179478"
    },
    {
      "nct_id": "NCT04660539",
      "title": "A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "satralizumab",
          "type": "DRUG"
        },
        {
          "name": "azathioprine (AZA)",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil (MMF)",
          "type": "DRUG"
        },
        {
          "name": "oral corticosteroids",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 119,
      "start_date": "2021-03-02",
      "completion_date": "2024-05-28",
      "has_results": true,
      "last_update_posted_date": "2024-12-27",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Miami, Florida • Columbus, Georgia + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Columbus",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Northbrook",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04660539"
    },
    {
      "nct_id": "NCT01623076",
      "title": "The Longitudinal CONQUER Study of Rare Neuroimmunologic Disorders",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder",
        "Transverse Myelitis",
        "Optic Neuritis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "6 Years and older"
      },
      "enrollment_count": 150,
      "start_date": "2012-06",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-01-06",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01623076"
    },
    {
      "nct_id": "NCT04155424",
      "title": "A Study of the Safety and Activity of Eculizumab in Pediatric Participants With Relapsing Neuromyelitis Optica Spectrum Disorder",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 5,
      "start_date": "2020-01-14",
      "completion_date": "2023-07-31",
      "has_results": true,
      "last_update_posted_date": "2024-09-25",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 15,
      "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Miami, Florida + 11 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04155424"
    },
    {
      "nct_id": "NCT01892345",
      "title": "A Randomized Controlled Trial of Eculizumab in AQP4 Antibody-positive Participants With NMO (PREVENT Study)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Eculizumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 143,
      "start_date": "2014-04-11",
      "completion_date": "2018-07-17",
      "has_results": true,
      "last_update_posted_date": "2019-06-26",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 19,
      "location_summary": "Scottsdale, Arizona • Carlsbad, California • Washington D.C., District of Columbia + 15 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01892345"
    },
    {
      "nct_id": "NCT04201262",
      "title": "An Efficacy and Safety Study of Ravulizumab in Adult Participants With NMOSD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neuromyelitis Optica",
        "Neuromyelitis Optica Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "Ravulizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Alexion Pharmaceuticals, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 58,
      "start_date": "2019-12-09",
      "completion_date": "2024-10-31",
      "has_results": true,
      "last_update_posted_date": "2025-10-14",
      "last_synced_at": "2026-07-23T07:31:21.008Z",
      "location_count": 10,
      "location_summary": "Aurora, Colorado • Fort Collins, Colorado • Washington D.C., District of Columbia + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Fort Collins",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04201262"
    }
  ]
}